While the data reported so far provide multiple therapeutic options for patients with r/r CLL, disease progression and especially refractory disease after pretreatment with both inhibitors of BTK and BCL2 still pose a challenge in daily clinical practice. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.